Compound
citric acid
A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
Structure
Loading the model…
- Class
- Organic compound
- Formula
- C6H8O7
- Mass
- 192.123 g/mol
- Charge
- 0
- InChIKey
- KRKNYBCHXYNGOX-UHFFFAOYSA-N
- SMILES
- O=C(O)CC(O)(CC(=O)O)C(=O)O
- Look it up
- ChEBIPubChemBy InChIKey
Identity from ChEBI, geometry from PubChem. Not evidence.
What it touches on the way
Mechanistic reach
13 entities
13 entities reached.
0 reported hops13 assembled from the scaffold
- SLC25A1ProteinUNIPROT:P53007transported byInferred only504 paths28 endpoints
- ACLYProteinUNIPROT:P53396substrate ofInferred only80 paths40 endpoints
- ANKHProteinUNIPROT:Q9HCJ1transported byInferred only44 paths44 endpoints
- ACO2ProteinUNIPROT:Q99798substrate ofInferred only40 paths20 endpoints
- ACO1ProteinUNIPROT:P21399substrate ofInferred only32 paths16 endpoints
- CSProteinUNIPROT:O75390substrate ofInferred only24 paths24 endpoints
- SLC13A2ProteinUNIPROT:Q13183transported byInferred only18 paths5 endpoints
- SLC13A5ProteinUNIPROT:Q86YT5transported byInferred only9 paths3 endpoints
- SFXN5ProteinUNIPROT:Q8TD22transported byInferred only8 paths8 endpoints
- SLC35G1ProteinUNIPROT:Q2M3R5transported byInferred only3 paths3 endpoints
- SLC13A3ProteinUNIPROT:Q8WWT9transported byInferred only3 paths3 endpoints
- RIMKLBProteinUNIPROT:Q9ULI2substrate ofInferred only3 paths3 endpoints
Show the remaining 1
What the reference databases state
Statements
56 statements
56 statements · 3 reference databases · Subject: citric acid · Sources: ChEBI, Human-GEM, Rhea
- beta-citrylglutamate is converted to citric acidCompoundRhea RHEA:86691Inferred only
- citric acid is converted to beta-citrylglutamateCompoundRhea RHEA:40043Inferred only
- citric acid is converted to beta-citrylglutamateCompoundRhea RHEA:86691Inferred only
- beta-citrylglutamate is converted to citric acidCompoundRhea RHEA:40043Inferred only
- calcium citrate is converted to citric acidCompoundChEBI CHEBI:190513Inferred only
- citric acid is converted to cis-aconitateCompoundRhea RHEA:10228Inferred only
- cis-aconitate is converted to citric acidCompoundRhea RHEA:10228Inferred only
- cis-aconitic acid is converted to citric acidCompoundHuman-GEM MAR04458Inferred only
- citric acid is converted to cis-aconitic acidCompoundHuman-GEM MAR04458Inferred only
- citric acid is converted to D-threo-isocitrateCompoundRhea RHEA:10336Inferred only
- D-threo-isocitrate is converted to citric acidCompoundRhea RHEA:10336Inferred only
- ferric ammonium citrate is converted to citric acidCompoundChEBI CHEBI:31604Inferred only
Show the remaining 44
- isocitric acid is converted to citric acidCompoundHuman-GEM MAR04454Inferred only
- citric acid is converted to isocitric acidCompoundHuman-GEM MAR04454Inferred only
- magnesium citrate is converted to citric acidCompoundChEBI CHEBI:131389Inferred only
- oxaloacetate is converted to citric acidCompoundRhea RHEA:16845Inferred only
- citric acid is converted to oxaloacetateCompoundRhea RHEA:21160Inferred only
- citric acid is converted to oxaloacetateCompoundRhea RHEA:16845Inferred only
- citric acid is a substrate of ACLYProteinHuman-GEM MAR04149Inferred only
- citric acid is a substrate of ACLYProteinRhea RHEA:21160Inferred only
- citric acid is a substrate of ACO1ProteinHuman-GEM MAR04454Inferred only
- citric acid is a substrate of ACO1ProteinRhea RHEA:10336Inferred only
- citric acid is a substrate of ACO2ProteinHuman-GEM MAR04458Inferred only
- citric acid is a substrate of ACO2ProteinRhea RHEA:10336Inferred only
- citric acid is a substrate of CSProteinRhea RHEA:16845Inferred only
- citric acid is a substrate of RIMKLBProteinRhea RHEA:40043Inferred only
- citric acid is transported by ANKHProteinRhea RHEA:33183Inferred only
- citric acid is transported by SFXN5ProteinRhea RHEA:33183Inferred only
- citric acid is transported by SLC13A2ProteinRhea RHEA:72195Inferred only
- citric acid is transported by SLC13A2ProteinHuman-GEM MAR05994Inferred only
- citric acid is transported by SLC13A2ProteinHuman-GEM MAR05995Inferred only
- citric acid is transported by SLC13A3ProteinHuman-GEM MAR05996Inferred only
- citric acid is transported by SLC13A5ProteinRhea RHEA:65664Inferred only
- citric acid is transported by SLC13A5ProteinHuman-GEM MAR05997Inferred only
- citric acid is transported by SLC13A5ProteinHuman-GEM MAR05994Inferred only
- citric acid is transported by SLC25A1ProteinHuman-GEM MAR06276Inferred only
- citric acid is transported by SLC25A1ProteinHuman-GEM MAR06286Inferred only
- citric acid is transported by SLC25A1ProteinHuman-GEM MAR06288Inferred only
- citric acid is transported by SLC25A1ProteinRhea RHEA:72487Inferred only
- citric acid is transported by SLC25A1ProteinHuman-GEM MAR06287Inferred only
- citric acid is transported by SLC25A1ProteinRhea RHEA:72471Inferred only
- citric acid is transported by SLC25A1ProteinHuman-GEM MAR02405Inferred only
- citric acid is transported by SLC25A1ProteinHuman-GEM MAR02406Inferred only
- citric acid is transported by SLC25A1ProteinHuman-GEM MAR00125Inferred only
- citric acid is transported by SLC25A1ProteinRhea RHEA:72491Inferred only
- citric acid is transported by SLC25A1ProteinHuman-GEM MAR04964Inferred only
- citric acid is transported by SLC25A1ProteinHuman-GEM MAR04971Inferred only
- citric acid is transported by SLC25A1ProteinHuman-GEM MAR04972Inferred only
- citric acid is transported by SLC25A1ProteinRhea RHEA:72483Inferred only
- citric acid is transported by SLC25A1ProteinRhea RHEA:72479Inferred only
- citric acid is transported by SLC25A1ProteinRhea RHEA:72475Inferred only
- citric acid is transported by SLC25A1ProteinRhea RHEA:28835Inferred only
- citric acid is transported by SLC25A1ProteinHuman-GEM MAR02220Inferred only
- citric acid is transported by SLC25A14ProteinRhea RHEA:33183Inferred only
- citric acid is transported by SLC25A21ProteinRhea RHEA:71763Inferred only
- citric acid is transported by SLC35G1ProteinRhea RHEA:33183Inferred only
Reactions
56 reactions
citric acid+(S)-malatecitric acid+(S)-malate
Transported by SLC25A1
Reaction pageReversibleBalancedEC 4.2.1.56cytosol, mitochondrial matrix
Human-GEM MAR00125CC BY 4.0Reference data
citric acid+succinate(2-)citric acid+succinate(2-)
Transported by SLC25A1
Reaction pageReversibleBalancedcytosol, mitochondrial matrix
Human-GEM MAR02220CC BY 4.0Reference data
2-oxoglutarate(2-)+citric acid2-oxoglutarate(2-)+citric acid
Transported by SLC25A1
Reaction pageReversibleBalancedcytosol, mitochondrial matrix
Human-GEM MAR02405CC BY 4.0Reference data
citric acid+oxalic acidcitric acid+oxalic acid
Transported by SLC25A1
Reaction pageReversibleBalancedmitochondrial matrix, cytosol
Human-GEM MAR02406CC BY 4.0Reference data
CHEBI:15351+water+oxaloacetatecitric acid+CHEBI:1146900+proton
Catalysed by CS
Reaction pageLeft to rightBalancedEC 2.3.3.1, 2.3.3.3mitochondrial matrix
Human-GEM MAR04145CC BY 4.0Reference data
ATP+citric acid+CHEBI:1146900CHEBI:15351+ADP+oxaloacetate+phosphate(3-)
Catalysed by ACLY
Reaction pageLeft to rightBalancedEC 2.3.3.8cytosol
Human-GEM MAR04149CC BY 4.0Reference data
Catalysed by ACO1
Reaction pageReversibleBalancedEC 4.2.1.3cytosol
Human-GEM MAR04454CC BY 4.0Reference data
cis-aconitic acid+watercitric acid
Catalysed by ACO2
Reaction pageReversibleBalancedEC 4.2.1.3mitochondrial matrix
Human-GEM MAR04458CC BY 4.0Reference data
Reaction pageLeft to rightBalancedmitochondrial matrix, cytosol
Human-GEM MAR04957CC BY 4.0Reference data
citric acid+proton+(S)-malatecitric acid+proton+(S)-malate
Transported by SLC25A1
Reaction pageLeft to rightBalancedmitochondrial matrix, cytosol
Human-GEM MAR04964CC BY 4.0Reference data
citric acid+phosphoenolpyruvic acidcitric acid+phosphoenolpyruvic acid
Transported by SLC25A1
Reaction pageReversibleBalancedmitochondrial matrix, cytosol
Human-GEM MAR04971CC BY 4.0Reference data
citric acid+isocitric acidcitric acid+isocitric acid
Transported by SLC25A1
Reaction pageReversibleBalancedcytosol, mitochondrial matrix
Human-GEM MAR04972CC BY 4.0Reference data
On the label
Labelled products
56 products
Source: NIH DSLD · Ingredient: citric acid · 56 products · Declared amount per serving: 5–2,000 mg (42 products)
43 labels state an amount13 do not
- AN Amazing Nutrition Amazing FormulasCitric Acid1 Gram(s)per 1 Gram(s)DSLD:251768
- AOR Advanced Orthomolecular Research AdvancedCardioNOx150 mgper 1 Capsule(s)DSLD:214551
- BiophixOxy Clenz 750 mg108 mgper 4 Capsule(s)DSLD:276062
- Body EcologyEcoOxyZyme15 mgper 1 Capsule(s)DSLD:241423
- Body EcologyRelease Intestinal Biofilm Cleanser15 mgper 1 Capsule(s)DSLD:314769
- Calcium Oxalate LabsKidney C.O.P.350 mgper 2 Delayed Release Vegetarian Capsule(s)DSLD:207062
- Calcium Oxalate LabsKidney C.O.P.350 mgper 2 Delayed Release Vegetarian Capsule(s)DSLD:251046
- Christopher's Original FormulasAcai Berry Blendamount not statedper 1 Fluid oz.DSLD:199816
- Christopher's Original FormulasGoji Juiceamount not statedper 1 Fluid oz.DSLD:200295
- Christopher's Original FormulasVital Juiceamount not statedper 1 Fluid oz.DSLD:200580
- doTERRAPB Assist Jr Strawberry Melon Flavoredamount not statedper 1 Not PresentDSLD:203004
- Dr. Clark StoreCitric Acid 590 mgCitric Acid Note: food grade590 mgper 1 Capsule(s)DSLD:219818
Show the remaining 44
- dr.boUric Acid Cleanse250 mgper 2 Capsule(s)DSLD:328706
- Drucker LabsintraMAX 2.0 Peach Mango Flavoramount not statedper 1 fl. Oz.DSLD:236722
- Earthborn ElementsCitric Acid1,200 mgper 2 Capsule(s)DSLD:319525
- Enriching GiftsCoral Life25 mgper 1 Capsule(s)DSLD:228200
- Essante OrganicspHyto Cleanse25 mgper 1 Capsule(s)DSLD:331457
- Global Healing CenterOxy-Powder90 mgper 4 Capsule(s)DSLD:231210
- Global Healing CenterOxy-Powder90 mgper 4 Capsule(s)DSLD:231212
- Hard RhinoPure Citric Acid Pharma Grade Powder2,000 mgper 2000 mgDSLD:34289
- Health Thru Nutrition NaturallyViva-Berry50 mgper 1 Vege Capsule(s)DSLD:51507
- Healthy KidneyStone Solution Lime Flavor5 mgper 5.6 Gram(s)DSLD:321246
- Higher NatureAloe GoldCitric Acid Note: acidity regulatoramount not statedper 10 mLDSLD:216884
- Higher NatureAloe GoldCitric Acid Note: acidity regulatoramount not statedper 10 mLDSLD:41524
- Higher NatureAloe Gold Cherry & CranberryCitric Acid Note: acidity regulatoramount not statedper 10 mLDSLD:223309
- Higher Nature KidsRelax & Unwind Mixed Berry Flavour301 mgper 9.4 Gram(s)DSLD:240542
- KirkmanDe-Tox Diet & Complexing Aid50 mgper 4 Capsule(s)DSLD:24055
- Magnum NutraceuticalsOpus Extreme Intra-Workout Juicy Watermelon50 mgper 9.25 Gram(s)DSLD:263195
- Magnum NutraceuticalsOpus Extreme Intra-Workout Twister Pop100 mgper 9.25 Gram(s)DSLD:263196
- Magnum NutraceuticalsOpus Red Berry Candy50 mgper 9.25 Gram(s)DSLD:236740
- MetagenicsCenitol800 mgper 7.4 Gram(s)DSLD:323367
- MetagenicsEndura Lemon-Lime Flavor990 mgper 35 Gram(s)DSLD:26772
- MetagenicsEndura Orange Flavor950 mgper 35 Gram(s)DSLD:26801
- Musclegen Performance NutritionPsychosis X Limeaide Fizz1,000 mgper 5.85 Gram(s)DSLD:213573
- Musclegen Performance NutritionPsychosis X Limeaide Fizz1,000 mgper 11.7 Gram(s)DSLD:249713
- Nature's CraftUric Acid Formula250 mgper 2 Vegetable Capsule(s)DSLD:296738
- Nature's CraftUric Acid Formula250 mgper 2 Vegetable Capsule(s)DSLD:321689
- Number One NutritionUric Acid Support250 mgper 2 Vegetable Capsule(s)DSLD:336005
- Nutra BioGenesisMuscle Aid400 mgper 5.37 Gram(s)DSLD:323006
- NutracraftUricPro250 mgper 2 Vegetable Capsule(s)DSLD:275619
- NutricostCitric Acid 1,000 mg1,000 mgper 1 Capsule(s)DSLD:306199
- NutricostCitric Acid 1,000 mg1,000 mgper 1 Capsule(s)DSLD:311684
- NutriONNUric Acid Support250 mgper 2 Vegetable Capsule(s)DSLD:308909
- PerqueLife Guard Mini Tabsules29.5 mgper 2 Tabsule(s)DSLD:18782
- PerqueLife Guard Mini Tabsules29.5 mgper 2 Tabsule(s)DSLD:18785
- PerqueLife Guard Mini Tabsules29.5 mgper 2 Tabsule(s)DSLD:240303
- Progressive Professional from Progressive LaboratoriesChitosan300 mgper 4 Capsule(s)DSLD:261536
- Prototype NutritionBAETamount not statedper 1 mLDSLD:264835
- Prototype NutritionDHEAamount not statedper 1 mLDSLD:264846
- PureMax Labs YummyViteUric Acid Advanced Formula250 mgper 2 Vegetable Capsule(s)DSLD:318876
- Simply YoungPure Body Cleanseactive homeopathic ingredient, citricum acidum 6xamount not statedper 1 Vegetable Capsule(s)DSLD:258261
- Soto SupplementsGFC 200+amount not statedper 10 Drop(s)DSLD:209984
- Teraputics Pure LifeUric Acid Support250 mgper 2 Capsule(s)DSLD:268761
- Trace Minerals ResearchMineral Mouth Rinse Mintamount not statedper 20 mLDSLD:66848
- USANARev3 Energy Surge Pack450 mgper 1 Packet(s)DSLD:322330
- Vibrant HealthGlycemic Vibrance H Natural Orange-Mango Flavor480 mgper 4 Gram(s)DSLD:40381
Label record: NIH Office of Dietary Supplements · CC0
Registered, and not reported
- Source
- ClinicalTrials.gov
- Intervention
- citric acid
- Status
- Completed, terminated or suspended
- Results posted
- No
Trials without posted results
342 trials
342 registered trials without posted results · Overdue (FDAAA 801): 109 · Showing 120 of 342
109 past the window11 within it, or no actual date
- NCT01810913suspended— Other - Assessing accrual feasibilityexpected 2027-01-01NIH
- NCT04386070suspended— Lack of IMP availability - may resume.expected 2026-12-31a university or hospital
- NCT07053774completed2026-06-01a university or hospital
- NCT07722351completed2026-04-01a university or hospital
- NCT07255820completed2026-03-30a university or hospital
- NCT06561711completed2026-02-21a university or hospital
- NCT07755735completed2026-01-12industry
- NCT07258628completed2026-01-10a university or hospital
- NCT07294846completed2025-12-15industry
- NCT06742853completed2025-10-29industry
- NCT06650930completed2025-10-11a university or hospitalpast the reporting window
- NCT05365477completed2025-09-26a university or hospitalpast the reporting window
Show the remaining 330
- NCT06983509completed2025-09-11industrypast the reporting window
- NCT04284657completed2025-08-04a university or hospitalpast the reporting window
- NCT05913817completed2025-07-31industrypast the reporting window
- NCT06724198completed2025-07-01a government bodypast the reporting window
- NCT03336918completed2025-06-30a university or hospitalpast the reporting window
- NCT07206329completed2025-06-30a university or hospitalpast the reporting window
- NCT05509413completed2025-05-23a university or hospitalpast the reporting window
- NCT05161468terminated— Funding limitation did not allow the trial to run to completion2025-05-12US federal agencypast the reporting window
- NCT06869824completed2025-04-13industrypast the reporting window
- NCT05877027completed2025-03-18a university or hospitalpast the reporting window
- NCT06251050completed2025-03-01a university or hospitalpast the reporting window
- NCT07122284completed2024-12-30a university or hospitalpast the reporting window
- NCT06736366completed2024-12-16a university or hospitalpast the reporting window
- NCT05814341completed2024-12-15a university or hospitalpast the reporting window
- NCT06763809completed2024-12-12industrypast the reporting window
- NCT04626609completed2024-11-01a university or hospitalpast the reporting window
- NCT07366372completed2024-11-01a university or hospitalpast the reporting window
- NCT07162974completed2024-10-30a university or hospitalpast the reporting window
- NCT05480761terminated— Lack of subject enrollment2024-09-18industrypast the reporting window
- NCT06472427completed2024-07-30a university or hospitalpast the reporting window
- NCT03809884completed2024-07-22a university or hospitalpast the reporting window
- NCT06570668completed2024-07-12a university or hospitalpast the reporting window
- NCT06058312completed2024-07-04a university or hospitalpast the reporting window
- NCT07408297completed2024-06-27a university or hospitalpast the reporting window
- NCT05890690completed2024-06-24a university or hospitalpast the reporting window
- NCT05178407completed2024-06-10a university or hospitalpast the reporting window
- NCT06321770completed2024-04-16a university or hospitalpast the reporting window
- NCT04598880completed2024-04-01a university or hospitalpast the reporting window
- NCT06994585completed2024-03-28a university or hospitalpast the reporting window
- NCT04213794terminated— slow accrual2024-03-04a university or hospitalpast the reporting window
- NCT06843850completed2024-03-01a university or hospitalpast the reporting window
- NCT06132269completed2024-01-30industrypast the reporting window
- NCT06148662completed2024-01-25a university or hospitalpast the reporting window
- NCT06122467completed2023-12-31industrypast the reporting window
- NCT06429306completed2023-11-24industrypast the reporting window
- NCT04329624completed2023-11-07a university or hospitalpast the reporting window
- NCT06018740completed2023-11-06industrypast the reporting window
- NCT05548465completed2023-10-31a university or hospitalpast the reporting window
- NCT04751669completed2023-10-26a university or hospitalpast the reporting window
- NCT05711290completed2023-08-08a university or hospitalpast the reporting window
- NCT03000101completed2023-07-19a university or hospitalpast the reporting window
- NCT05592951completed2023-07-14a university or hospitalpast the reporting window
- NCT03276481completed2023-07-12a university or hospitalpast the reporting window
- NCT06051175completed2023-07-01a university or hospitalpast the reporting window
- NCT06339697completed2023-06-30a university or hospitalpast the reporting window
- NCT02391025completed2023-06-15a university or hospitalpast the reporting window
- NCT07398924completed2023-06-06a university or hospitalpast the reporting window
- NCT04787926terminated— Enrollment was low or halted with few to zero future anticipated enrollments.2023-06-01industrypast the reporting window
- NCT05974982completed2023-05-25a government bodypast the reporting window
- NCT04106362terminated— low enrollment2023-05-23a university or hospitalpast the reporting window
- NCT05231980completed2023-05-06a university or hospitalpast the reporting window
- NCT04422184completed2023-05-03a university or hospitalpast the reporting window
- NCT06565728completed2023-05-01a university or hospitalpast the reporting window
- NCT03597555completed2023-04-12a university or hospitalpast the reporting window
- NCT05488886completed2023-03-28a university or hospitalpast the reporting window
- NCT04683796completed2023-02-28a university or hospitalpast the reporting window
- NCT02436226completed2023-01a university or hospitalpast the reporting window
- NCT04444765completed2022-12-31a university or hospitalpast the reporting window
- NCT04474002completed2022-12-31a university or hospitalpast the reporting window
- NCT05191290completed2022-12-30a university or hospitalpast the reporting window
- NCT03281928terminated— Study closed due to IRB expiration. A new protocol (IRB22-1817) was submitted to continue the research.2022-11-15a university or hospitalpast the reporting window
- NCT05407701completed2022-11-15a university or hospitalpast the reporting window
- NCT06244186completed2022-11-01a university or hospitalpast the reporting window
- NCT05589051completed2022-10-28a university or hospitalpast the reporting window
- NCT04784234terminated— company was bought and discontinued producing supplement2022-10-27a university or hospitalpast the reporting window
- NCT05523115completed2022-10-01industrypast the reporting window
- NCT05493553completed2022-09-29industrypast the reporting window
- NCT05260346completed2022-08-22a university or hospitalpast the reporting window
- NCT04297839suspended— DUE TO CORONAVIRUS DISEASE, ACTIVITIES INTHE HOSPITAL ARE SUPRESSEDexpected 2022-07-31a university or hospital
- NCT07027670completed2022-06-30a university or hospitalpast the reporting window
- NCT05272228completed2022-05-15a university or hospitalpast the reporting window
- NCT05510791completed2022-05-10a university or hospitalpast the reporting window
- NCT02921893completed2022-04-21a university or hospitalpast the reporting window
- NCT05100589completed2022-04-19a university or hospitalpast the reporting window
- NCT03945812completed2022-03-31a university or hospitalpast the reporting window
- NCT04741620completed2022-03-27a university or hospitalpast the reporting window
- NCT04226586completed2022-03-15a university or hospitalpast the reporting window
- NCT05294939completed2022-02-05a university or hospitalpast the reporting window
- NCT05290298completed2022-02-01a university or hospitalpast the reporting window
- NCT05177614completed2022-01-28a university or hospitalpast the reporting window
- NCT04985396completed2022-01-26a government bodypast the reporting window
- NCT03631446completed2021-12-31industrypast the reporting window
- NCT03399539completed2021-12-20a university or hospitalpast the reporting window
- NCT05154968completed2021-12-14industrypast the reporting window
- NCT03894657completed2021-11-25a university or hospitalpast the reporting window
- NCT05008549completed2021-11-01industrypast the reporting window
- NCT06042738completed2021-11-01a university or hospitalpast the reporting window
- NCT04542850completed2021-08-31a university or hospitalpast the reporting window
- NCT04898686completed2021-08-06a university or hospitalpast the reporting window
- NCT04095975completed2021-06-24a university or hospitalpast the reporting window
- NCT04896294completed2021-06-21a university or hospitalpast the reporting window
- NCT04483908completed2021-05-30a university or hospitalpast the reporting window
- NCT04764565completed2021-04-06a university or hospitalpast the reporting window
- NCT05149053completed2021-02-26a university or hospitalpast the reporting window
- NCT01217372completed2021-02-16a university or hospitalpast the reporting window
- NCT04554342completed2021-02-10a university or hospitalpast the reporting window
- NCT03578419completed2021-01-21a university or hospitalpast the reporting window
- NCT04865510completed2021-01-15a government bodypast the reporting window
- NCT04566549completed2020-12-06industrypast the reporting window
- NCT05143398completed2020-10-15a university or hospitalpast the reporting window
- NCT02923128completed2020-10a university or hospitalpast the reporting window
- NCT02504359completed2020-09-09a university or hospitalpast the reporting window
- NCT03984409completed2020-08-31a university or hospitalpast the reporting window
- NCT04305080completed2020-08-15a university or hospitalpast the reporting window
- NCT02622854completed2020-08a university or hospitalpast the reporting window
- NCT03367494terminated— Investigator Decision2020-06-01a university or hospitalpast the reporting window
- NCT00867178completed2020-04-09NIHpast the reporting window
- NCT03425747completed2020-04-01a university or hospitalpast the reporting window
Where it reaches
8 systems, 19 regions, 80 tissues, 92 transporter routes — routes, not measurements: transporters known to carry citric acid are expressed there, and no source reports it arriving.
Loading the model…
Papers screened
1,023 papers
- Compound
- citric acid
- Screened
- 1,023
- Admitted
- 0
- Discarded
- 796
- Not read
- 227
- Showing
- 200 of 1,023
Discarded: the wrong intervention699 papers
- PMID:11055288cited by PMID:20557687; not about the subject it would be filed under2026-10-13
- PMID:11331897cited by PMID:20557687; not about the subject it would be filed under2026-10-13
- PMID:11749171cited by PMID:20557687; not about the subject it would be filed under2026-10-13
- PMID:11755704cited by PMID:20557687; not about the subject it would be filed under2026-10-13
- PMID:11866568cited by PMID:20557687; not about the subject it would be filed under2026-10-13
- PMID:11943384cited by PMID:20557687; not about the subject it would be filed under2026-10-13
- PMID:12003078cited by PMID:20557687; not about the subject it would be filed under2026-10-13
- PMID:12042865cited by PMID:20557687; not about the subject it would be filed under2026-10-13
- PMID:12219820cited by PMID:20557687; not about the subject it would be filed under2026-10-13
- PMID:12219826cited by PMID:20557687; not about the subject it would be filed under2026-10-13
- PMID:12741789cited by PMID:20557687; not about the subject it would be filed under2026-10-13
- PMID:15110477cited by PMID:20557687; not about the subject it would be filed under2026-10-13
and 687 more.
Discarded: another reason, stated per paper46 papers
- PMID:25903061no claim extracted — subject_absent — DOSED: QMix, BioPure MTAD and 17% EDTA root canal irrigants (abstract never names citric acid) | QMix, BioPure MTAD, 17% EDTA and saline final irrigants; the abstract never names citric acid2026-10-12
- PMID:26863933no claim extracted — cause not determined2026-10-12
- PMID:29346835no claim extracted — cause not determined (one pass only) — measured: root citrate secretion under aluminum stress in plants2026-10-12
- PMID:31901688no claim extracted — cause not determined — DOSED: iC-EPE citrate-based mussel-inspired bioadhesive (citric acid, PEG-PPG-PEG diol, dopamine) crosslinked with MgO, abstract2026-10-12
- PMID:33624931no claim extracted — other2026-10-12
- PMID:34797950no claim extracted — cause not determined — DOSED: poly(citric acid-1,8-octanediol-BHEp) (POPC) / beta-TCP 3D-printed scaffold, abstract2026-10-12
- PMID:20800893no claim extracted — subject_absent — DOSED: poly(ethylene glycol) maleate citrate (PEGMC) citric acid-derived polymer, abstract | Poly(ethylene glycol) maleate citrate (PEGMC) and crosslinked PPEGMC hydrogels, a polymer, abstract only2026-10-11
- PMID:22902057no claim extracted — subject_absent — DOSED: injectable citrate-based mussel-inspired bioadhesives (iCMBAs; citric acid/PEG/dopamine oligomers), Methods 2.2 | Injectable citrate-based mussel-inspired bioadhesives (iCMBAs), oligomers of citric acid, PEG and dopamine, Methods 2.22026-10-11
- PMID:23465824no claim extracted — subject_absent — DOSED: urethane-doped biodegradable photoluminescent polymers (UBPLPs), citrate-based elastomers, abstract | Urethane-doped citrate-based biodegradable photoluminescent polymers (UBPLPs), a material, abstract only2026-10-11
- PMID:24829094no claim extracted — subject_absent — DOSED: poly(octanediol citrate)-click-hydroxyapatite (POC-Click-HA) biphasic scaffolds, abstract | Citrate-based poly(octanediol citrate)-click-hydroxyapatite (POC-Click-HA) biphasic scaffolds, implanted in rabbits, abstract only2026-10-11
- PMID:25372769no claim extracted — subject_absent — DOSED: citric acid-based polymer/hydroxyapatite composite scaffolds (POC-Click-HA, CUPE-HA), abstract | Citric acid-based polymer/hydroxyapatite scaffolds (POC-Click-HA, CUPE-HA), implanted in rat calvarial defects, abstract only2026-10-11
- PMID:27770631no claim extracted — subject_absent — DOSED: injectable citrate-based mussel-inspired bioadhesives (iCMBAs; citric acid/PEG/dopamine polymers), Results | Injectable citrate-based mussel-inspired bioadhesives (iCMBAs), crosslinked polymers; citric acid is a monomer, Results2026-10-11
and 34 more.
Discarded: not retrievable29 papers
- PMID:16746382no PMID parsed, abstract under 200 characters, or no record returned by efetch2026-09-29
- PMID:32310492no PMID parsed, abstract under 200 characters, or no record returned by efetch2026-09-29
and 27 more.
Discarded: an endpoint this vocabulary does not hold14 papers
- PMID:24850836claims extracted but the object named resolved to no node — recorded in candidate_nodes (ADR-0070)2026-10-12
- PMID:29040793claims extracted but the object named resolved to no node — recorded in candidate_nodes (ADR-0070)2026-10-12
- PMID:31176009no claim extracted — vocabulary gap, passes disagreed: no_outcome_node / endpoint_near_miss — measured: intestinal tissue gene expression (qPCR) of TLR pathway, cytokines and tight junction proteins in fish; serum IgM and complement C4 concentration | intestinal TNF-α mRNA expression by qPCR in turbot (node requires circulating TNF-α protein by immunoassay)2026-10-12
- PMID:31745774no claim extracted — endpoint_near_miss — measured: malondialdehyde content in C. elegans whole-worm homogenate; SOD and GPx activity in worm lysate (nodes require plasma, serum, whole blood or erythrocyte) | whole-worm malondialdehyde content in C. elegans (node requires circulating MDA in plasma, serum or blood)2026-10-12
- PMID:34371126claims extracted but the object named resolved to no node — recorded in candidate_nodes (ADR-0070)2026-10-12
- PMID:35841232no claim extracted — no_outcome_node — measured: hair growth / hair cycle catagen entry in mice, morphology and histopathology | hair growth / hair follicle catagen entry, morphology and histopathology in mice2026-10-12
- PMID:16820438claims extracted but the object named resolved to no node — recorded in candidate_nodes (ADR-0070)2026-10-11
- PMID:24433072no claim extracted — vocabulary gap, passes disagreed: endpoint_near_miss / no_outcome_node — measured: malondialdehyde in brain and liver tissue homogenate (not circulating); TNF-alpha in brain tissue (not serum/plasma) | brain tissue malondialdehyde (lipid peroxidation) in LPS-challenged mice; tissue homogenate, assay not stated in abstract2026-10-11
- PMID:39515533no claim extracted — no_outcome_node — measured: plant tissue cadmium accumulation and bioconcentration factor, stem and leaf; leaf malondialdehyde (not circulating) | plant tissue cadmium accumulation / bioconcentration factor in Brassica napus, pot experiment2026-10-11
- PMID:31257152claims extracted but the object named resolved to no node — recorded in candidate_nodes (ADR-0070)2026-09-29
- PMID:35717669no claim extracted — no_outcome_node — measured: antimicrobial inhibition of S. aureus and E. coli, percentage inhibition assay | antimicrobial activity, percentage inhibition of S. aureus and E. coli growth2026-09-29
and 3 more.
Discarded: no extractable result7 papers
and 7 more.
Discarded: no comparator1 paper
and 1 more.
Not read yet227 papers
- PMID:128690032026-10-09
- PMID:180393362026-10-09
- PMID:156490482026-10-01
- PMID:109757502026-09-29
- PMID:114640422026-09-29
- PMID:123891242026-09-29
- PMID:208470412026-09-29
- PMID:215645532026-09-29
- PMID:222643462026-09-29
- PMID:233067822026-09-29
- PMID:238522332026-09-29
- PMID:245213052026-09-29
and 215 more.
Measured, not recorded
- Compound
- citric acid
- Endpoints measured
- 224 endpoints
- Recorded as a finding
- No
Show what was measured
blood glycerol
increases, n = 7
Only Caff increased plasma epinephrine (P<0.05), but both MX increased blood glycerol levels (P<0.05).
PMID:11053334 · one of two readings recorded this
blood glycerol
increases, n = 7
Only Caff increased plasma epinephrine (P<0.05), but both MX increased blood glycerol levels (P<0.05).
PMID:11053334 · one of two readings recorded this
muscle cAMP
increases, n = 7
Muscle cAMP was increased (P<0.05) by both MX at 15 min and remained elevated at 45 min with Theo.
PMID:11053334 · one of two readings recorded this
muscle cAMP
increases, n = 7
Muscle cAMP was increased (P<0.05) by both MX at 15 min and remained elevated at 45 min with Theo.
PMID:11053334 · one of two readings recorded this
muscle glycogen utilization
no effect, n = 7
Neither methylxanthines (MX) affected muscle glycogen utilization (P>0.05).
PMID:11053334 · one of two readings recorded this
muscle glycogen utilization
no effect, n = 7
Neither methylxanthines (MX) affected muscle glycogen utilization (P>0.05).
PMID:11053334 · one of two readings recorded this
plasma epinephrine
increases, n = 7
Only Caff increased plasma epinephrine (P<0.05), but both MX increased blood glycerol levels (P<0.05).
PMID:11053334 · one of two readings recorded this
plasma epinephrine
increases, n = 7
Only Caff increased plasma epinephrine (P<0.05), but both MX increased blood glycerol levels (P<0.05).
PMID:11053334 · one of two readings recorded this
time to exhaustion, cycling at 80% max O2 consumption
increases, Caff 41.2+/-4.8 min, Theo 37.4+/-5.0 min vs placebo 32.6+/-3.4 min, n = 8
There was a significant increase in time to exhaustion in both the Caff (41.2+/-4.8 min) and Theo (37.4+/-5.0 min) trials compared with placebo (32.6+/-3.4 min) (P<0.05).
PMID:11053334 · one of two readings recorded this
time to exhaustion cycling at 80% maximum O2 consumption, 90 min after ingestion
increases, Caff 41.2+/-4.8 min and Theo 37.4+/-5.0 min vs placebo 32.6+/-3.4 min, n = 8
Not recorded as a finding: subject_absent
There was a significant increase in time to exhaustion in both the Caff (41.2+/-4.8 min) and Theo (37.4+/-5.0 min) trials compared with placebo (32.6+/-3.4 min) (P<0.05).
PMID:11053334 · one of two readings recorded this
time to exhaustion, cycling at 80% VO2max
increases, Caff 41.2+/-4.8 min and Theo 37.4+/-5.0 min vs placebo 32.6+/-3.4 min, n = 8
There was a significant increase in time to exhaustion in both the Caff (41.2+/-4.8 min) and Theo (37.4+/-5.0 min) trials compared with placebo (32.6+/-3.4 min) (P<0.05).
PMID:11053334 · one of two readings recorded this
time to exhaustion during cycling at 80% maximum O2 consumption after ingestion of caffeine, theophylline, or placebo
increases, Caff 41.2+/-4.8 min and Theo 37.4+/-5.0 min vs placebo 32.6+/-3.4 min, n = 8
Not recorded as a finding: subject_absent
There was a significant increase in time to exhaustion in both the Caff (41.2+/-4.8 min) and Theo (37.4+/-5.0 min) trials compared with placebo (32.6+/-3.4 min) (P<0.05).
PMID:11053334 · one of two readings recorded this
citrate inhibition of 49-kDa PFK1 fragment
no effect
On the other hand, the shorter fragment of PFK1 proved to be completely resistant to inhibition by citrate
PMID:16820438 · one of two readings recorded this
citrate inhibition of 85-kDa native PFK1 relieved by magnesium
decreases
while increasing magnesium concentrations relieved the negative effect of citrate
PMID:16820438 · one of two readings recorded this
cell proliferation/adhesion (MTT assay)
decreases
Quantitative MTT analysis show that cells proliferated better on PLLA films when compared to non-collagen-immobilized POMC films.
PMID:20557687 · one of two readings recorded this
subcutaneous foreign-body fibrous capsule thickness
decreases, 284.29 ± 25.42 μm (POMC) vs 312.38 ± 20.20 μm (PLLA)
The thickness of the cell layers are 284.29 ± 25.42 μm for POMC and 312.38 ± 20.20 μm for PLLA.
PMID:20557687 · one of two readings recorded this
compressive strain without permanent deformation
Cyclic conditioning tests showed that PPEGMC hydrogels could be compressed up to 75% strain without permanent deformation and with negligible hysteresis
PMID:20800893 · one of two readings recorded this
time to complete degradation in vivo
PPEGMC elicited minimal inflammation in the early stages post-injection and was completely degraded within 30 days in rats
PMID:20800893 · one of two readings recorded this
CD11b positive inflammatory cells in incision area
no effect
By day 28th there was a negligible number of inflammatory cells for both groups (iCMBA: 92±42 #/mm2; suture: 107±50 #/mm2)
PMID:22902057 · one of two readings recorded this
CD11b positive inflammatory cells in incision area
no effect
Similarly the number of CD11b positive inflammatory cells in the incisions area at seventh day post treatment was not significantly different in iCMBA-treated wounds (1771±242 #/mm2) and sutured wounds (1592±142 #/mm2)
PMID:22902057 · one of two readings recorded this
cell viability in degradation products at 1x
no effect
iCMBA degradation products (1×) showed a cell viability of at least 72.9±9 %
PMID:22902057 · one of two readings recorded this
cell viability in sol-content leachate at 1x
decreases
The cytotoxicity of the leachable content (sol content) of crosslinked iCMBAs at 1× concentration was between of 60±4 and 83±14 %
PMID:22902057 · one of two readings recorded this
collagen density
increases
a higher amount of collagen was found at the sites of rat's iCMBA-treated wounds (7th day= 15±12 %; 28th day= 63±4 %) than those treated with sutures (7th day= 17±9 %; 28th day= 58±7 %) on day 28th
PMID:22902057 · one of two readings recorded this
collagen density
a higher amount of collagen was found at the sites of rat's iCMBA-treated wounds (7th day= 15±12 %; 28th day= 63±4 %) than those treated with sutures (7th day= 17±9 %; 28th day= 58±7 %) on day 28th
PMID:22902057 · one of two readings recorded this
dry-state elongation at break (highest)
In the dry state, the highest measured values for tensile strength, elongation at break and tensile modulus were 8515.1±1167 kPa (iCMBA-P200D0.3 PI:8%), 1582.5±144.6 % (iCMBA-P400D0.3 PI:4%) and 35.7±6.7 MPa (iCMBA-P200D0.3 PI:8%), respectively
PMID:22902057 · one of two readings recorded this
dry-state tensile modulus (highest)
In the dry state, the highest measured values for tensile strength, elongation at break and tensile modulus were 8515.1±1167 kPa (iCMBA-P200D0.3 PI:8%), 1582.5±144.6 % (iCMBA-P400D0.3 PI:4%) and 35.7±6.7 MPa (iCMBA-P200D0.3 PI:8%), respectively
PMID:22902057 · one of two readings recorded this
dry-state tensile strength (highest)
In the dry state, the highest measured values for tensile strength, elongation at break and tensile modulus were 8515.1±1167 kPa (iCMBA-P200D0.3 PI:8%), 1582.5±144.6 % (iCMBA-P400D0.3 PI:4%) and 35.7±6.7 MPa (iCMBA-P200D0.3 PI:8%), respectively
PMID:22902057 · one of two readings recorded this
gel time
The measured gel time was in the range of 18 seconds for iCMBA-P400D0.5 PI:8% at 37°C up to slightly over 5 minutes for iCMBA-P400D0.3 PI:2%
PMID:22902057 · one of two readings recorded this
gel time
The measured gel time was in the range of 18 seconds for iCMBA-P400D0.5 PI:8% at 37°C up to slightly over 5 minutes for iCMBA-P400D0.3 PI:2%
PMID:22902057 · one of two readings recorded this
lap shear adhesion strength (highest iCMBA)
The lap shear adhesion strength of different iCMBA formulations varied between 33.4±8.9 kPa (for iCMBA-P200D0.3 PI:2%) and 123.2±13.2 kPa (for iCMBA-P1000D0.3 PI:8%)
PMID:22902057 · one of two readings recorded this
lap shear adhesion strength (lowest iCMBA)
The lap shear adhesion strength of different iCMBA formulations varied between 33.4±8.9 kPa (for iCMBA-P200D0.3 PI:2%) and 123.2±13.2 kPa (for iCMBA-P1000D0.3 PI:8%)
PMID:22902057 · one of two readings recorded this
lap shear adhesion strength
commercially available fibrin glue with the adhesion strength measured at 15.4±2.8 kPa
PMID:22902057 · one of two readings recorded this
pre-polymer cell viability (NIH 3T3, MTT)
decreases
At the concentration of 10mg/mL (pre-polymer/cell culture medium) the cell viability was between 66±6 and 78±11 % of that in the blank medium
PMID:22902057 · one of two readings recorded this
pre-polymer cell viability (NIH 3T3, MTT)
which was comparable to the value for control solution (PEGDA 700) at 78±7 %
PMID:22902057 · one of two readings recorded this
sol content (highest)
iCMBA-P400D0.3 PI:2% had the highest sol content of about 34%
PMID:22902057 · one of two readings recorded this
sol content (lowest)
iCMBA-P400D0.5 and iCMBA-P200D0.3, both crosslinked with PI:8% (w/w PI/pre-polymer), showed the lowest amount of sol content of 2.37% and 2.86%, respectively
PMID:22902057 · one of two readings recorded this
sol content (lowest)
iCMBA-P400D0.5 and iCMBA-P200D0.3, both crosslinked with PI:8% (w/w PI/pre-polymer), showed the lowest amount of sol content of 2.37% and 2.86%, respectively
PMID:22902057 · one of two readings recorded this
swelling percentage (lowest)
iCMBA-P400D0.5 PI:8%, having the highest amount of dopamine content and crosslinked with high PI-to-iCMBA ratio, demonstrated the lowest swelling percentage with 471.8%
PMID:22902057 · one of two readings recorded this
swelling ratio (highest)
iCMBA-P1000D0.3 PI:8%, which consists of PEG 1000, displayed the highest swollen ratio at approximately 3400%
PMID:22902057 · one of two readings recorded this
tensile strength of regenerated rat skin
increases
the iCMBA-treated skin had better tensile strength (1250±315 kPa) than suture-closed skin (810±355 kPa)
PMID:22902057 · one of two readings recorded this
time to complete degradation in PBS at 37°C
iCMBA-P400D0.5 PI:8% exhibited the slowest rate of degradation, 25 days for complete degradation in PBS at 37°C
PMID:22902057 · one of two readings recorded this
total cell density in incision area
no effect
The difference between total cell densities in the incision area treated by iCMBA (7th day= 3996±264 #/mm2; 28th day= 3202±227 #/mm2) and suture (7th day: 4117±269 #/mm2; 28th day: 2992±163 #/mm2) was not significant
PMID:22902057 · one of two readings recorded this
total cell density in incision area
no effect
The difference between total cell densities in the incision area treated by iCMBA (7th day= 3996±264 #/mm2; 28th day= 3202±227 #/mm2) and suture (7th day: 4117±269 #/mm2; 28th day: 2992±163 #/mm2) was not significant
PMID:22902057 · one of two readings recorded this
5-fluorouracil loading efficiency
High loading efficiency (91.84%) and sustained release of 5-fluorouracil (up to 120 h) were achieved from UBPLP nanoparticles
PMID:23465824 · one of two readings recorded this
5-fluorouracil sustained release duration
High loading efficiency (91.84%) and sustained release of 5-fluorouracil (up to 120 h) were achieved from UBPLP nanoparticles
PMID:23465824 · one of two readings recorded this
burst pressure
Porous triphasic CUBPLP vascular scaffolds showed a burst pressure of 769.33 ± 70.88 mmHg and a suture retention strength of 1.79 ± 0.11 N
PMID:23465824 · one of two readings recorded this
elongation at break
Crosslinked UBPLPs (CUBPLPs) showed soft, elastic, but strong mechanical properties with a tensile strength as high as 49.41 ± 6.17 MPa and a corresponding elongation at break of 334.87 ± 26.31%
PMID:23465824 · one of two readings recorded this
fluorescence quantum yield
With a quantum yield as high as 38.65%, both triphasic scaffold and nanoparticle solutions could be non-invasively detected in vivo
PMID:23465824 · one of two readings recorded this
nanoparticle average size
Stable but photoluminescent nanoparticles with average size of 103 nm were also obtained by nanoprecipitation
PMID:23465824 · one of two readings recorded this
suture retention strength
Porous triphasic CUBPLP vascular scaffolds showed a burst pressure of 769.33 ± 70.88 mmHg and a suture retention strength of 1.79 ± 0.11 N
PMID:23465824 · one of two readings recorded this
tensile strength
Crosslinked UBPLPs (CUBPLPs) showed soft, elastic, but strong mechanical properties with a tensile strength as high as 49.41 ± 6.17 MPa and a corresponding elongation at break of 334.87 ± 26.31%
PMID:23465824 · one of two readings recorded this
brain and liver MDA, nitrite, TNF-α (brain) after LPS alone
increases
LPS induced oxidative stress in the brain and liver tissue, resulting in marked increase in lipid peroxidation (malondialdehyde [MDA]) and nitrite
PMID:24433072 · one of two readings recorded this
brain and liver tissue malondialdehyde (lipid peroxidation), nitrite, TNF-alpha, glutathione peroxidase and paraoxonase 1 activity in LPS-treated mice
decreases, citric acid 1-2 g/kg attenuated LPS-induced elevation of brain MDA
Not recorded as a finding: a node exists but the paper states a different instrument or population
The administration of citric acid (1-2 g/kg) attenuated LPS-induced elevations in brain MDA, nitrite, TNF-α, GPx, and PON1 activity.
PMID:24433072 · one of two readings recorded this
brain and liver tissue malondialdehyde, nitrite, TNF-alpha, glutathione peroxidase and paraoxonase 1 activity in LPS-treated mice
decreases, citric acid 1-2 g/kg attenuated LPS-induced elevations in brain MDA, nitrite, TNF-α, GPx and PON1 activity
Not recorded as a finding: this platform holds no node for the endpoint
The administration of citric acid (1-2 g/kg) attenuated LPS-induced elevations in brain MDA, nitrite, TNF-α, GPx, and PON1 activity.
PMID:24433072 · one of two readings recorded this
brain glutathione peroxidase (GPx) activity
modulates
The administration of citric acid (1-2 g/kg) attenuated LPS-induced elevations in brain MDA, nitrite, TNF-α, GPx, and PON1 activity
PMID:24433072 · one of two readings recorded this
brain malondialdehyde (lipid peroxidation)
decreases
The administration of citric acid (1-2 g/kg) attenuated LPS-induced elevations in brain MDA, nitrite, TNF-α, GPx, and PON1 activity
PMID:24433072 · one of two readings recorded this
brain nitrite
decreases
The administration of citric acid (1-2 g/kg) attenuated LPS-induced elevations in brain MDA, nitrite, TNF-α, GPx, and PON1 activity
PMID:24433072 · one of two readings recorded this
brain paraoxonase 1 (PON1) activity
modulates
The administration of citric acid (1-2 g/kg) attenuated LPS-induced elevations in brain MDA, nitrite, TNF-α, GPx, and PON1 activity
PMID:24433072 · one of two readings recorded this
brain TNF-α
decreases
The administration of citric acid (1-2 g/kg) attenuated LPS-induced elevations in brain MDA, nitrite, TNF-α, GPx, and PON1 activity
PMID:24433072 · one of two readings recorded this
liver caspase-3
decreases
The LPS-induced liver injury, DNA fragmentation, serum transaminase elevations, caspase-3, and inducible nitric oxide synthase expression were attenuated by 1-2 g/kg citric acid
PMID:24433072 · one of two readings recorded this
liver DNA fragmentation at high dose
increases
DNA fragmentation, however, increased after 4 g/kg citric acid
PMID:24433072 · one of two readings recorded this
liver DNA fragmentation
decreases
The LPS-induced liver injury, DNA fragmentation, serum transaminase elevations, caspase-3, and inducible nitric oxide synthase expression were attenuated by 1-2 g/kg citric acid
PMID:24433072 · one of two readings recorded this
liver GPx activity
increases
GPx activity was increased, while PON1 activity was decreased by citric acid
PMID:24433072 · one of two readings recorded this
liver inducible nitric oxide synthase expression
decreases
The LPS-induced liver injury, DNA fragmentation, serum transaminase elevations, caspase-3, and inducible nitric oxide synthase expression were attenuated by 1-2 g/kg citric acid
PMID:24433072 · one of two readings recorded this
liver injury
decreases
The LPS-induced liver injury, DNA fragmentation, serum transaminase elevations, caspase-3, and inducible nitric oxide synthase expression were attenuated by 1-2 g/kg citric acid
PMID:24433072 · one of two readings recorded this
liver nitrite
decreases
In the liver, nitrite was decreased by 1 g/kg citric acid
PMID:24433072 · one of two readings recorded this
liver PON1 activity
decreases
GPx activity was increased, while PON1 activity was decreased by citric acid
PMID:24433072 · one of two readings recorded this
serum transaminases
decreases
The LPS-induced liver injury, DNA fragmentation, serum transaminase elevations, caspase-3, and inducible nitric oxide synthase expression were attenuated by 1-2 g/kg citric acid
PMID:24433072 · one of two readings recorded this
compression strength, interfacial bone ingrowth, periosteal remodeling at 15 weeks
no effect
Biomechanical and histomorphometric analysis supported a similar outcome with biphasic scaffolds providing increased compression strength, interfacial bone ingrowth, and periosteal remodeling in early time points, but were comparable to all experimental groups after 15 weeks
PMID:24829094 · one of two readings recorded this
compressive strength of biphasic POC-Click-HA scaffolds
Biphasic POC-Click-HA scaffolds displayed compressive strengths up to 37.45 ± 3.83 MPa, which could be controlled through the external phase porosity
PMID:24829094 · one of two readings recorded this
new bone formation and bone density, early stages
increases
Biphasic scaffolds significantly enhanced new bone formation with higher bone densities in the initial stages after implantation
PMID:24829094 · one of two readings recorded this
Al tolerance and citrate secretion in Arabidopsis
increases
Compared with the wild-type Arabidopsis, the transgenic lines constitutively overexpressing BoMATE enhanced Al tolerance and increased citrate secretion
PMID:24850836 · one of two readings recorded this
BoMATE expression, roots versus shoots
increases
The expression of BoMATE was more abundant in roots than in shoots, and it was highly induced by Al treatment
PMID:24850836 · one of two readings recorded this
BoMATE expression
increases
The expression of BoMATE was more abundant in roots than in shoots, and it was highly induced by Al treatment
PMID:24850836 · one of two readings recorded this
citrate efflux
increases
The (14)C-citrate efflux experiments in oocytes demonstrated that BoMATE is a citrate transporter
PMID:24850836 · one of two readings recorded this
H(+) efflux in distal elongation zone
increases
Arabidopsis transgenic lines had a lower K(+) efflux and higher H(+) efflux, in the presence of Al, than control wild type in the distal elongation zone (DEZ)
PMID:24850836 · one of two readings recorded this
K(+) efflux in distal elongation zone
decreases
Arabidopsis transgenic lines had a lower K(+) efflux and higher H(+) efflux, in the presence of Al, than control wild type in the distal elongation zone (DEZ)
PMID:24850836 · one of two readings recorded this
bone mineral density, trabecular thickness and angiogenesis
increases
Both, POC-Click-HA and CUPE-HA scaffolds, resulted in enhanced bone mineral density, trabecular thickness, and angiogenesis when compared to the control groups at 1, 3, and 6 months post-trauma
PMID:25372769 · one of two readings recorded this
osteogenesis (radiological and histological)
increases
Radiological and histological data showed a significant enhancement of osteogenesis in defects treated with CUPE-HA scaffolds when compared to POC-Click-HA scaffolds
PMID:25372769 · one of two readings recorded this
sealer penetration into dentinal tubules
decreases, p = 0.05
MG and CG presented the lowest penetrability values (P < .05)
PMID:25903061 · one of two readings recorded this
sealer penetration into dentinal tubules
no effect, p = 0.05
QG and EG presented similar amounts of sealer penetration (P > .05)
PMID:25903061 · one of two readings recorded this
smear layer removal, apical third
increases, p = 0.05
The best results for smear layer removal of the apical third of the root canal were achieved by the QG and EG groups when compared with MG and CG (P < .05)
PMID:25903061 · one of two readings recorded this
fasting glycaemia, glucose tolerance and adipose tissue cytokine expression in mice given citrate or citrate+sucrose in drinking water
increases, augmented fasting glycaemia and glucose intolerance in citrate+sucrose group
Not recorded as a finding: the intervention held more than the compound
However, the group receiving citrate+sucrose showed augmented fasting glycaemia, glucose intolerance and the expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6 and IL-10) in their AT.
PMID:26863933 · one of two readings recorded this
fasting glycaemia
increases
the group receiving citrate+sucrose showed augmented fasting glycaemia, glucose intolerance and the expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6 and IL-10) in their AT
PMID:26863933 · one of two readings recorded this
glucose tolerance
decreases
the group receiving citrate+sucrose showed augmented fasting glycaemia, glucose intolerance and the expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6 and IL-10) in their AT
PMID:26863933 · one of two readings recorded this
liver, skeletal muscle and adipose tissue weight
no effect
mice receiving citrate or citrate+sucrose did not show increased weight gain or an increase in the weight of the liver, skeletal muscles or adipose tissues (AT)
PMID:26863933 · one of two readings recorded this
plasma lipid profile (TAG, total cholesterol, LDL and HDL), weight gain, fasting glycaemia, glucose tolerance, adipose tissue cytokine expression in mice given citrate in drinking water with or without sucrose
no effect, plasma lipid profiles similar across all groups
Not recorded as a finding: the supporting sentence never names the compound
Moreover, the plasma lipid profiles (TAG, total cholesterol, LDL and HDL) were similar across all groups.
PMID:26863933 · one of two readings recorded this
plasma lipid profile (TAG, total cholesterol, LDL, HDL)
no effect
the plasma lipid profiles (TAG, total cholesterol, LDL and HDL) were similar across all groups
PMID:26863933 · one of two readings recorded this
pro-inflammatory cytokine expression (TNF-α, IL-1β, IL-6, IL-10)
increases
the group receiving citrate+sucrose showed augmented fasting glycaemia, glucose intolerance and the expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6 and IL-10) in their AT
PMID:26863933 · one of two readings recorded this
weight gain
no effect
mice receiving citrate or citrate+sucrose did not show increased weight gain or an increase in the weight of the liver, skeletal muscles or adipose tissues (AT)
PMID:26863933 · one of two readings recorded this
bacterial inhibition ratio against S. aureus and E. coli, PI-crosslinked iCs, 24 hours
increases
The bacterial inhibition ratios of iCs and clickable iCs crosslinked by PI against S. au or E. coli were still higher than 90% or 60%, respectively, after 24 hours
PMID:27770631 · one of two readings recorded this
bacterial inhibition ratio of iC-X-PIs after 24 hours of incubation
increases
they remained at ~70% against S. au or ~50% against E. coli even after 24 hours of incubation
PMID:27770631 · one of two readings recorded this
complete degradation time of crosslinked clickable iCs
Complete degradation could be realized in 35 days in all formulas tested
PMID:27770631 · one of two readings recorded this
elongation at break of crosslinked iCs
All of the crosslinked iCs exhibited elastic behavior with their elongation at break higher than 150%
PMID:27770631 · one of two readings recorded this
fungal survival, dual-crosslinked clickable iCs
only ~ 10% fungal survival was observed
PMID:27770631 · one of two readings recorded this
fungal survival, Hydrofera Blue
crosslinked iCs, including the CuAAC crosslinked one, all exhibited better fungal inhibition effect than Hydrofera Blue (~ 25% fungal survival)
PMID:27770631 · one of two readings recorded this
gel time of dual-crosslinked clickable iCs
The gel times of dual-crosslinked clickable iCs crosslinked by CuSO4-NaLAc-PI-HEPES at 37 °C were below 5 minutes for all the formulations tested
PMID:27770631 · one of two readings recorded this
hMSC viability with Cu2+ and NaLAc
both Cu2+ and NaLAc treated hMSCs showed cell viability higher than 85% when the concentrations were lower than 1000 μmol/L
PMID:27770631 · one of two readings recorded this
optimal HEPES concentration for fastest gelation
Among the investigated formulations, 20 mM of HEPES was found to generate the quickest crosslinking for all the three CuSO4/NaLAc ratios used
PMID:27770631 · one of two readings recorded this
sol content of dual-crosslinked iC-X-PI versus PI-crosslinked iCs
decreases
whereas dual-crosslinked clickable iCs (iC-X-PI) possessed much lower sol contents (all < 5%) than iCs crosslinked by PI (~17.5%)
PMID:27770631 · one of two readings recorded this
wet adhesion strength, PI-only versus click plus dual crosslinking
increases
The introduction of click chemistry and the application of dual crosslinking mechanism vastly improved the wet adhesion strength of iCs (from ~50 kPa for iC-P4-PI 8 wt% to ~223 kPa for GL-iC-P2/4-X-PI 4 wt%)
PMID:27770631 · one of two readings recorded this
wet adhesion strength versus fibrin glue
increases
Most importantly, the highest adhesion strength achieved (223.11 ± 15.94 kPa) during the test was approximately 13 times higher than that of commercially available fibrin at 15.4 ± 2.8 kPa
PMID:27770631 · one of two readings recorded this
wet tissue lap shear strength range across clickable iC formulations
The various formulations of clickable iC showed wet tissue lap shear strengths ranging from 41.21 ± 4.48 kPa (for iC-P4-X) to 223.11 ± 15.94 kPa (for GL-iC-P2/4-X-PI 4 wt%)
PMID:27770631 · one of two readings recorded this
cyclooxygenase-2 synthesis
decreases
CWG inhibited secretion of the pro-inflammatory cytokines tumor necrosis factor-α, interleukin (IL)-6, and IL-12 and the synthesis of cyclooxygenase-2, while UWG only decreased IL-12 production
PMID:28698513 · one of two readings recorded this
IL-10 and heme oxygenase-1 levels
increases
CWG and UWG induced high levels of anti-inflammatory IL-10 and heme oxygenase-1
PMID:28698513 · one of two readings recorded this
IL-12 production
decreases
CWG inhibited secretion of the pro-inflammatory cytokines tumor necrosis factor-α, interleukin (IL)-6, and IL-12 and the synthesis of cyclooxygenase-2, while UWG only decreased IL-12 production
PMID:28698513 · one of two readings recorded this
IL-12 secretion
decreases
CWG inhibited secretion of the pro-inflammatory cytokines tumor necrosis factor-α, interleukin (IL)-6, and IL-12 and the synthesis of cyclooxygenase-2, while UWG only decreased IL-12 production
PMID:28698513 · one of two readings recorded this
IL-6 secretion
decreases
CWG inhibited secretion of the pro-inflammatory cytokines tumor necrosis factor-α, interleukin (IL)-6, and IL-12 and the synthesis of cyclooxygenase-2, while UWG only decreased IL-12 production
PMID:28698513 · one of two readings recorded this
phosphorylation of NF-κB p65 and p38 kinase
decreases
CWG specifically inhibited phosphorylation of NF-κB p65 and p38 kinase at 15 min after LPS stimulation
PMID:28698513 · one of two readings recorded this
TNF-α secretion
decreases
CWG inhibited secretion of the pro-inflammatory cytokines tumor necrosis factor-α, interleukin (IL)-6, and IL-12 and the synthesis of cyclooxygenase-2, while UWG only decreased IL-12 production
PMID:28698513 · one of two readings recorded this
total phenolic and total flavonoid contents
decreases
Treatment of wheat germ with citric acid resulted in detectable release of DMBQ but reduced total phenolic and total flavonoid contents compared with untreated wheat germ extract (UWG)
PMID:28698513 · one of two readings recorded this
optical loss of citrate-based step-index optical fiber
we developed a two-step fabrication method to fabricate flexible and low-loss (0.4 db/cm) optical fibers
PMID:28802101 · one of two readings recorded this
Al-induced citrate secretion in transgenic Arabidopsis
increases
Expression of FeMATE1 also partially recovered the Al-induced secretion of citrate in the transgenic lines, whereas expression of FeMATE2 did not complement the citrate secretion
PMID:29040793 · one of two readings recorded this
Al-induced citrate secretion in transgenic Arabidopsis
no effect
Expression of FeMATE1 also partially recovered the Al-induced secretion of citrate in the transgenic lines, whereas expression of FeMATE2 did not complement the citrate secretion
PMID:29040793 · one of two readings recorded this
Al tolerance of Arabidopsis atmate mutant
increases
Heterologous expression of FeMATE1 or FeMATE2 in the Arabidopsis mutant atmate partially rescued its Al tolerance
PMID:29040793 · one of two readings recorded this
citrate and oxalate secretion from buckwheat roots
increases
buckwheat roots also secreted citrate in addition to oxalate in response to Al in a dose-responsive manner
PMID:29040793 · one of two readings recorded this
citrate efflux transport activity
increases
Both FeMATE1 and FeMATE2 showed efflux transport activity for citrate, but not for oxalate when expressed in Xenopus oocytes
PMID:29040793 · one of two readings recorded this
FeMATE1 and FeMATE2 expression
no effect
the expression of both genes only responded to Al toxicity, but not to other stresses including low pH, cadmium (Cd) and lanthanum (La)
PMID:29040793 · one of two readings recorded this
FeMATE1 expression
increases
The expression of FeMATE1 was induced by Al only in the roots, but that of FeMATE2 was up-regulated in both the roots and leaves
PMID:29040793 · one of two readings recorded this
FeMATE2 expression
increases
The expression of FeMATE1 was induced by Al only in the roots, but that of FeMATE2 was up-regulated in both the roots and leaves
PMID:29040793 · one of two readings recorded this
oxalate efflux transport activity
no effect
Both FeMATE1 and FeMATE2 showed efflux transport activity for citrate, but not for oxalate when expressed in Xenopus oocytes
PMID:29040793 · one of two readings recorded this
Al-induced citrate secretion from rice bean root apex
increases
Al-induced citrate secretion from the rice bean root apex is biphasic, consisting of an early phase with low secretion and a later phase of large citrate secretion
PMID:29346835 · one of two readings recorded this
Al-induced VuMATE1 expression
decreases
While a protein translation inhibitor suppressed Al-induced VuMATE1 expression, it releases VuMATE2 expression
PMID:29346835 · one of two readings recorded this
anion efflux in Xenopus oocytes
increases
Electrophysiological analysis of Xenopus oocytes expressing VuMATE2 indicated VuMATE2 mediates anion efflux
PMID:29346835 · one of two readings recorded this
root citrate secretion and Al resistance in Arabidopsis
increases
Ectopic expression of VuMATE2 in Arabidopsis resulted in increased root citrate secretion and Al resistance
PMID:29346835 · one of two readings recorded this
VuMATE2 expression
increases
While a protein translation inhibitor suppressed Al-induced VuMATE1 expression, it releases VuMATE2 expression
PMID:29346835 · one of two readings recorded this
distal intestine mRNA expression of TLRs, NF-kB, TNF-alpha, IFN-gamma and tight junction proteins, and serum IgM and C4, in juvenile turbot fed soybean meal diet with or without citric acid
decreases
Not recorded as a finding: this platform holds no node for the endpoint
Compared to the SBM, the concentration of IgM and C4 in serum was significantly reduced by dietary citric acid.
PMID:31176009 · one of two readings recorded this
gene expression of pro-inflammatory cytokines (TNF-α, IFN-γ) and Claudin-7
decreases
citric acid supplementation in SBM markedly depressed gene expression of pro-inflammatory cytokines (TNF-α and IFN-γ) and pore-forming tight junction protein Claudin-7
PMID:31176009 · one of two readings recorded this
gene expression of TGF-β1 and tight junction proteins (Claudin-3, Claudin-4, Occludin, Tricellulin, ZO-1)
increases
enhanced gene expression of the anti-inflammatory cytokine TGF-β1 and TJ proteins related to the decrease in paracellular permeability (Claudin-3, Claudin-4, Occludin, Tricellulin and ZO-1)
PMID:31176009 · one of two readings recorded this
gene expression of TLRs, MyD88 and TLR related molecules (NF-κB, IRF-3, p38, JNK)
increases
Compared to the FM, diet SBM significantly increased the gene expression of TLRs (TLR2, TLR3, TLR5b, TLR9, TLR21, TLR22) and MyD88
PMID:31176009 · one of two readings recorded this
gene expression of TLRs, MyD88 and TLR related molecules (NF-κB, IRF-3, p38, JNK)
decreases
as well as TLR related molecules (NF-κB, IRF-3, p38 and JNK), which were remarkably reduced by dietary citric acid
PMID:31176009 · one of two readings recorded this
serum IgM and C4 concentration
decreases
Compared to the SBM, the concentration of IgM and C4 in serum was significantly reduced by dietary citric acid
PMID:31176009 · one of two readings recorded this
circulating citrate contribution to kidney TCA cycle, 13C-tracer infusion and renal arteriovenous uptake ranking
increases, 20% contribution to kidney TCA cycle, fourth largest renal uptake after lactate, uric acid, and glutamine
Not recorded as a finding: this platform holds no node for the endpoint
The quantitative contribution of circulating citrate to the kidney TCA cycle was 20%, in the same range as glutamine and lactate.
PMID:31257152 · one of two readings recorded this
contribution of circulating citrate to kidney TCA cycle
increases, 20% contribution to kidney TCA cycle, in the same range as glutamine and lactate
The quantitative contribution of circulating citrate to the kidney TCA cycle was 20%, in the same range as glutamine and lactate.
PMID:31257152 · one of two readings recorded this
contribution of infused 13C-citrate to kidney TCA cycle intermediates
increases, large contribution to kidney TCA cycle; quantitative contribution of circulating citrate to the kidney TCA cycle was 20%
The quantitative contribution of circulating citrate to the kidney TCA cycle was 20%, in the same range as glutamine and lactate.
PMID:31257152 · one of two readings recorded this
contribution of infused 13C-malate and 13C-succinate to kidney TCA cycle, compared with citrate
no effect, malate and succinate did not make a comparable contribution in kidney, nor a major contribution in other organs
Malate and succinate did not make a comparable contribution in kidney, nor did any of these make a major contribution in other organs (Fig. S3D).
PMID:31257152 · one of two readings recorded this
malate and succinate contribution to kidney TCA cycle (comparator tracers)
no effect, did not make a comparable contribution in kidney
Malate and succinate did not make a comparable contribution in kidney, nor did any of these make a major contribution in other organs (Fig. S3D).
PMID:31257152 · one of two readings recorded this
renal arteriovenous uptake of circulating citrate relative to other metabolites
increases, fourth largest renal uptake after lactate, uric acid, and glutamine
Indeed, citrate showed the fourth largest renal uptake after lactate, uric acid, and glutamine (Fig. S3B).
PMID:31257152 · one of two readings recorded this
renal (kidney) uptake of circulating citrate relative to other circulating metabolites
increases, citrate is fourth largest renal uptake after lactate, uric acid, and glutamine
Indeed, citrate showed the fourth largest renal uptake after lactate, uric acid, and glutamine (Fig. S3B).
PMID:31257152 · one of two readings recorded this
renal uptake ranking of circulating (endogenous) citrate among TCA intermediates and other circulating metabolites
increases, fourth largest renal uptake among circulating metabolites, after lactate, uric acid, and glutamine
Not recorded as a finding: endogenous circulating citrate concentration/uptake comparison, not an administered exposure (no tracer or dose given for this measurement); no outcome node exists for a renal metabolite-uptake ranking
Indeed, citrate showed the fourth largest renal uptake after lactate, uric acid, and glutamine (Fig. S3B).
PMID:31257152 · one of two readings recorded this
basic movements
increases
basic movements by 1.0- to 1.5-fold
PMID:31745774 · one of two readings recorded this
citric acid content
increases
the citric acid content increased by approximately 3-fold in the cadmium (Cd, 5 μM), zinc (Zn, 10 μM), and copper (Cu, 100 μM) treatment groups compared to that in untreated C. elegans
PMID:31745774 · one of two readings recorded this
GPx activity
decreases
the GPx activity by 4.0- to 3.0-fold
PMID:31745774 · one of two readings recorded this
GPx mRNA expression
decreases
the mRNA expression levels of GPxs by 3.2- to 1.8-fold after metals treatment
PMID:31745774 · one of two readings recorded this
LC50 of metals
increases
Excess citric acid also slightly increased the LC50 by 1.3- to 2.0-fold
PMID:31745774 · one of two readings recorded this
MDA content
decreases
the MDA content by 4- to 2-fold
PMID:31745774 · one of two readings recorded this
MDA content
increases
The MDA content increased by approximately 7-, 5-, 2-fold after exposure to high concentrations of cadmium, zinc, and copper, respectively
PMID:31745774 · one of two readings recorded this
ROS content
decreases
decreased the ROS content by 2.4- to 2.1-fold
PMID:31745774 · one of two readings recorded this
ROS levels
increases
ROS levels increased by 1.3- to 2.1-fold with increasing metal concentrations
PMID:31745774 · one of two readings recorded this
SOD activity
decreases
the SOD activity by 9- to 3-fold
PMID:31745774 · one of two readings recorded this
adhesion strength
8 fold that of fibrin glue (~15 kPa)
PMID:31901688 · one of two readings recorded this
adhesion strength
increases
high adhesion strength (up to 125 kPa, 8 fold that of fibrin glue (~15 kPa))
PMID:31901688 · one of two readings recorded this
degradation time
modulates
tunable degradability (full degradation from <1 week to > 1 month)
PMID:31901688 · one of two readings recorded this
in vitro and in vivo biocompatibility, anti-bacterial performance and wound closure
unclear
excellent in vitro and in vivo biocompatibility, encouraging anti-bacterial performance, and favorable wound closure efficacy
PMID:31901688 · one of two readings recorded this
tensile strength
increases
iC-EPE crosslinked by MgO with/without sodium periodate (PI) exhibit enhanced mechanical strengths
PMID:31901688 · one of two readings recorded this
tensile strength
iC-EPE crosslinked only by PI (~0.75 MPa)
PMID:31901688 · one of two readings recorded this
adhesive capability of the AP polymer patch to rat cardiac tissue, compared to currently used patch materials
increases, demonstrates negligible cytotoxicity and improves adhesive capability to rat cardiac tissue compared to currently used patch materials
Not recorded as a finding: subject_absent
The selected polymer formulation, referred to as the adhesive patch (AP) polymer, demonstrates negligible cytotoxicity and improves adhesive capability to rat cardiac tissue compared to currently used patch materials.
PMID:32567253 · one of two readings recorded this
adhesive capability to rat cardiac tissue and cytotoxicity
increases, negligible cytotoxicity and improved adhesive capability compared to currently used patch materials
The selected polymer formulation, referred to as the adhesive patch (AP) polymer, demonstrates negligible cytotoxicity and improves adhesive capability to rat cardiac tissue compared to currently used patch materials.
PMID:32567253 · one of two readings recorded this
adhesive capability to rat cardiac tissue
increases, improves adhesive capability compared to currently used patch materials
The selected polymer formulation, referred to as the adhesive patch (AP) polymer, demonstrates negligible cytotoxicity and improves adhesive capability to rat cardiac tissue compared to currently used patch materials.
PMID:32567253 · one of two readings recorded this
endothelial cell adhesion, migration and proliferation
increases
distinct advantages of the CA functionalized nitinol stent over commercial Zilver PTX DES and Zilver Flex BMS stents in terms of endothelial cell adhesion, migration, and proliferation are reported
PMID:33624931 · one of two readings recorded this
fed and fasted insulin and insulin secretion during oral glucose tolerance test
increases
animals supplemented with citrate in their food displayed fed and fasted hyperinsulinemia and enhanced insulin secretion during an oral glucose tolerance test
PMID:34371126 · one of two readings recorded this
glucose and insulin tolerance tests, fed and fasted insulin, in C57BL/6J mice given citrate-supplemented chow for 24 hours
increases
Not recorded as a finding: this platform holds no node for the endpoint
Animals supplemented with dietary citrate showed glucose intolerance and insulin resistance as revealed by glucose and insulin tolerance tests.
PMID:34371126 · one of two readings recorded this
glucose-induced insulin secretion
increases
Citrate treatment also amplified glucose-induced insulin secretion in vitro in INS1-E cells
PMID:34371126 · one of two readings recorded this
glucose tolerance and insulin sensitivity, glucose and insulin tolerance tests
increases
Not recorded as a finding: no outcome node for glucose/insulin tolerance test results; fasting-blood-glucose node requires venous enzymatic assay after overnight fast, not stated
Animals supplemented with dietary citrate showed glucose intolerance and insulin resistance as revealed by glucose and insulin tolerance tests.
PMID:34371126 · one of two readings recorded this
glucose tolerance and insulin sensitivity
decreases
Animals supplemented with dietary citrate showed glucose intolerance and insulin resistance as revealed by glucose and insulin tolerance tests
PMID:34371126 · one of two readings recorded this
hepatic lipogenic gene expression
increases
citrate supplementation enhanced the hepatic expression of lipogenic genes suggesting increased de novo lipogenesis, a finding that was reproduced after citrate treatment of hepatic FAO cells
PMID:34371126 · one of two readings recorded this
liver inflammation markers
increases
liver inflammation markers were higher in citrate supplemented animals
PMID:34371126 · one of two readings recorded this
liver PKCα activity
increases
Citrate supplemented animals had increased liver PKCα activity and altered phosphorylation at serine or threonine residues of components of insulin signaling including IRS-1, Akt, GSK-3 and FoxO1
PMID:34371126 · one of two readings recorded this
acid environment / pH of POPC
modulates
The results reveal that the alkaline fragment BHEp effectively corrects the acid environment and improves the biocompatibility, cells affinity and promoted cell adhesion, and proliferation of POPC
PMID:34797950 · one of two readings recorded this
adhesion and proliferation of rabbit bone marrow mesenchymal stem cells and osteogenesis-related gene expression
increases
the improved pH of POPC15/β-TCP (PTCP15) enhances the adhesion and the proliferation of rabbit bone marrow mesenchymal stem cells, and the expression of osteogenesis-related genes
PMID:34797950 · one of two readings recorded this
bone regeneration and biocompatibility
increases
The rat femoral defect model further demonstrates good biocompatibility and enhanced bone regeneration of PTCP15
PMID:34797950 · one of two readings recorded this
inflammatory response and macrophage polarisation
decreases
Moreover, PTCP15 scaffolds relieve inflammatory response and switch RAW 264.7 toward a prohealing extreme
PMID:34797950 · one of two readings recorded this
antimicrobial activity, percentage inhibition of S. aureus and E. coli growth
increases, ≈100% and 55% inhibition of S. aureus and E. coli
Not recorded as a finding: this platform holds no node for the endpoint
Simultaneously, citrate's bioactive properties result in antimicrobial (≈100% and 55% inhibition of S. aureus and E. coli) and osteopromotive effects.
PMID:35717669 · one of two readings recorded this
antimicrobial inhibition of S. aureus and E. coli by the citrate-based polymer/hydroxyapatite putty, percentage inhibition
increases, ~100% and 55% inhibition of S. aureus and E. coli, respectively
Not recorded as a finding: this platform holds no node for the endpoint
Simultaneously, citrate's bioactive properties result in antimicrobial (≈100% and 55% inhibition of S. aureus and E. coli) and osteopromotive effects.
PMID:35717669 · one of two readings recorded this
antimicrobial inhibition of S. aureus and E. coli
increases, ~100% and 55% inhibition of S. aureus and E. coli, respectively
Simultaneously, citrate's bioactive properties result in antimicrobial (≈100% and 55% inhibition of S. aureus and E. coli) and osteopromotive effects.
PMID:35717669 · both readings recorded this
in vivo bone regeneration in a critical-sized rat calvaria defect
no effect, equivalent to gold standard autograft
BPLP-Ser/HA putty demonstrates in vivo regeneration in a critical-sized rat calvaria model equivalent to gold standard autograft.
PMID:35717669 · one of two readings recorded this
in vivo bone regeneration in a critical-sized rat calvaria model versus autograft
no effect, regeneration equivalent to gold standard autograft
Finally, BPLP-Ser/HA putty demonstrates in vivo regeneration in a critical-sized rat calvaria model equivalent to gold standard autograft.
PMID:35717669 · one of two readings recorded this
CA production and CA-induced hair growth inhibition, anagen shrink, inflammation and apoptosis
decreases
knockdown of CS reduced CA production and reversed CA-induced hair growth inhibition, anagen shrink, inflammation, and apoptosis both in HFs and DPCs
PMID:35841232 · one of two readings recorded this
dermal papilla cell proliferation, apoptosis and cell cycle
decreases
CA hampered the proliferation rate of DPCs via inducing cell apoptosis and cell cycle arrest
PMID:35841232 · one of two readings recorded this
hair growth, skin lesion, inflammatory response, apoptosis and catagen entry
decreases
subcutaneous injection of CA in mice caused significant hair growth suppression, skin lesion, inflammatory response, cell apoptosis, and promotion of catagen entry, compared with the saline control
PMID:35841232 · one of two readings recorded this
hair shaft production and catagen entry
decreases
In cultured human HFs, CA attenuated the hair shaft production and accelerated HF catagen entry by regulating the above-mentioned pathways
PMID:35841232 · one of two readings recorded this
mouse hair growth suppression and catagen entry after subcutaneous citric acid injection versus saline, by morphology and histopathology
decreases
Not recorded as a finding: this platform holds no node for the endpoint
We found that subcutaneous injection of CA in mice caused significant hair growth suppression, skin lesion, inflammatory response, cell apoptosis, and promotion of catagen entry, compared with the saline control, by activating p-p65 and apoptosis signaling in an NLRP3-dependent manner.
PMID:35841232 · one of two readings recorded this
antibacterial inhibition zone (S. aureus, E. coli)
unclear
There was no E. coli observed for all the tested films, while different sizes of inhibition zones were noted for S. aureus (in the range between 15 and 20 mm) (Table 2).
PMID:37537220 · one of two readings recorded this
film water solubility / crosslinking
increases
The neat Ch-film cast from the acetic acid solution disintegrated in water, while the Ch-DES and Ch–DES-A films retained their solid state.
PMID:37537220 · one of two readings recorded this
adverse bleeding reaction incidence
decreases, RR = 0.14 (95% CI 0.06 to 0.32)
Adverse bleeding reactions were significantly less common in the citrate group compared to the heparin group, with a statistically significant difference (RR = 0.14, 95% CI = 0.06 ~ 0.32, P = .000).
PMID:37652410 · one of two readings recorded this
dialysis filter lifespan
increases, WMD = 6.93 (95% CI 6.30 to 7.55)
The filter lifespan in the citrate group was significantly longer than in the heparin group, with a statistically significant difference (WMD = 6.93, 95% CI = 6.30 ~ 7.55, P = .000).
PMID:37652410 · one of two readings recorded this
renal function improvement, serum creatinine, urea nitrogen, filter lifespan, and adverse bleeding reaction incidence during continuous renal replacement therapy
increases, WMD = 6.93 (95% CI 6.30 to 7.55) longer filter lifespan with citrate vs heparin, n = 652
Not recorded as a finding: the comparison was against another active treatment
The filter lifespan in the citrate group was significantly longer than in the heparin group, with a statistically significant difference (WMD = 6.93, 95% CI = 6.30 ~ 7.55, P = .000).
PMID:37652410 · one of two readings recorded this
metallic sensation intensity rating
decreases, n = 121
The results revealed that metallic sensation ratings were significantly lower for every binary mixture tested compared to ferrous sulfate presented in isolation.
PMID:38147162 · one of two readings recorded this
metallic sensation intensity ratings for ferrous sulfate mixtures on a Labeled Magnitude Scale
decreases
Not recorded as a finding: this platform holds no node for the endpoint
For 0.3 mM ferrous sulfate, sucrose was identified to be the most effective compound in suppressing metallic sensation, followed by citric acid and sodium chloride.
PMID:38147162 · one of two readings recorded this
metallic sensation ratings for ferrous sulfate presented alone versus in binary mixture with citric acid
decreases, n = 121
Not recorded as a finding: this platform holds no node for the endpoint
The results revealed that metallic sensation ratings were significantly lower for every binary mixture tested compared to ferrous sulfate presented in isolation.
PMID:38147162 · one of two readings recorded this
perceived intensity of metallic taste sensation from ferrous sulfate, rated by participants in binary mixtures with citric acid, sucrose, or sodium chloride
decreases, metallic sensation ratings significantly lower for citric acid mixtures than ferrous sulfate alone, n = 121
Not recorded as a finding: this platform holds no node for the endpoint
The results revealed that metallic sensation ratings were significantly lower for every binary mixture tested compared to ferrous sulfate presented in isolation.
PMID:38147162 · one of two readings recorded this
body weight
increases
Compared to the control group (0 g/L), the body weights of the mice in both groups with concentration levels of 0.05 g/L and 0.1 g/L increased.
PMID:38279237 · one of two readings recorded this
cecal Bifidobacterium abundance, RT-qPCR copy number
increases
Not recorded as a finding: no CAT:outcome node exists for gut microbial genus abundance
In comparison to the control group (0 g/L), the concentration of Bifidobacteria in the group with a 0.1 g/L concentration exhibited a remarkably significant increase.
PMID:38279237 · one of two readings recorded this
cecal Bifidobacterium and Lactobacillus abundance
increases
In comparison to the control group (0 g/L), the concentration of Bifidobacteria in the group with a 0.1 g/L concentration exhibited a remarkably significant increase.
PMID:38279237 · one of two readings recorded this
cecal Escherichia coli abundance, RT-qPCR copy number
no effect
Not recorded as a finding: no CAT:outcome node exists for gut microbial genus abundance
The analysis of the Escherichia coli revealed no significant difference in the number of bacteria within the various groups.
PMID:38279237 · one of two readings recorded this
H9N2 avian influenza-induced inflammatory cytokine expression (TNF-α, IL-6) and viral replication in IEC-6 cells
decreases
Figure 7A–C shows a significant decrease in the expression of the intracellular tight junction gene claudin-1 upon infection with H9N2 AIV.
PMID:38279237 · one of two readings recorded this
intestinal tight junction gene expression (occludin, ZO-1, claudin-1 mRNA)
increases
Not recorded as a finding: no CAT:outcome node exists for tight junction gene expression
Figure 3A–D shows that in the intestinal tissues of mice, the mRNA expression of occludin, ZO-1, and claudin-1 was significantly or highly significantly increased in the 0.05 and 0.1 g/L concentration groups compared with the control group (0 g/L).
PMID:38279237 · one of two readings recorded this
intestinal tight junction gene expression (occludin, ZO-1, claudin-1)
increases
Figure 3A–D shows that in the intestinal tissues of mice, the mRNA expression of occludin, ZO-1, and claudin-1 was significantly or highly significantly increased in the 0.05 and 0.1 g/L concentration groups compared with the control group (0 g/L).
PMID:38279237 · one of two readings recorded this
small intestinal villus-crypt ratio, intestinal microbiota composition, tight-junction gene expression, and influenza virus replication in mice and IEC-6 cells
increases
Not recorded as a finding: this platform holds no node for the endpoint
Citric acid enhances the small intestinal villus-crypt ratio in mice, thereby promoting intestinal structural morphology.
PMID:38279237 · one of two readings recorded this
small intestinal villus-to-crypt ratio
increases
Not recorded as a finding: no CAT:outcome node exists for intestinal villus-crypt ratio
Table 1 demonstrates the data on the crypt ratio of the intestinal villi, indicating a significant increase in all experimental groups compared to the control group (0 g/L).
PMID:38279237 · one of two readings recorded this
Other names
6 names
Resolves to: citric acid
- Also called
- 2-Hydroxy-1,2,3-propanetricarboxylic acid2-Hydroxytricarballylic acid3-Carboxy-3-hydroxypentane-1,5-dioic acidE330H3cit
- Systematic name
- 2-hydroxypropane-1,2,3-tricarboxylic acid